• Je něco špatně v tomto záznamu ?

Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study

S. Michlewska, M. Maly, D. Wójkowska, K. Karolczak, E. Skiba, M. Hołota, M. Kubczak, P. Ortega, C. Watala, F. Javier de la Mata, M. Bryszewska, M. Ionov

. 2023 ; 636 (-) : 122784. [pub] 20230228

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010490

The carbosilane metallodendrimer G1-[[NCPh(o-N)Ru(η6- p-cymene)Cl]Cl]4 (CRD13), based on an arene Ru(II) complex coordinated to imino-pyridine surface groups, has been conjugated with anti-cancer drugs. Ruthenium in the positively-charged dendrimer structure allows this nanoparticle to be considered as an anticancer drug carrier, made more efficient because ruthenium has anticancer properties. The ability of CRD13 to form complexes with Doxorubicin (DOX), 5-Fluorouracil (5-Fu), and Methotrexate (MTX) has been evaluated using zeta potential measurement, transmission electron microscopy (TEM) and computer simulation. The results show that it forms stable nanocomplexes with all those drugs, enhancing their effectiveness against MDA-MB-231 cancer cells. In vivo tests indicate that the CRD13/DOX system caused a decrease of tumor weight in mice with triple negative breast cancer. However, the tumors were most visibly reduced when naked dendrimers were injected.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010490
003      
CZ-PrNML
005      
20230801132447.0
007      
ta
008      
230718s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpharm.2023.122784 $2 doi
035    __
$a (PubMed)36858135
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Michlewska, Sylwia $u Laboratory of Microscopic Imaging and Specialized Biological Techniques, Faculty of Biology and Environmental Protection, University of Lodz, Poland; Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland. Electronic address: sylwia.michlewska@biol.uni.lodz.pl
245    10
$a Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study / $c S. Michlewska, M. Maly, D. Wójkowska, K. Karolczak, E. Skiba, M. Hołota, M. Kubczak, P. Ortega, C. Watala, F. Javier de la Mata, M. Bryszewska, M. Ionov
520    9_
$a The carbosilane metallodendrimer G1-[[NCPh(o-N)Ru(η6- p-cymene)Cl]Cl]4 (CRD13), based on an arene Ru(II) complex coordinated to imino-pyridine surface groups, has been conjugated with anti-cancer drugs. Ruthenium in the positively-charged dendrimer structure allows this nanoparticle to be considered as an anticancer drug carrier, made more efficient because ruthenium has anticancer properties. The ability of CRD13 to form complexes with Doxorubicin (DOX), 5-Fluorouracil (5-Fu), and Methotrexate (MTX) has been evaluated using zeta potential measurement, transmission electron microscopy (TEM) and computer simulation. The results show that it forms stable nanocomplexes with all those drugs, enhancing their effectiveness against MDA-MB-231 cancer cells. In vivo tests indicate that the CRD13/DOX system caused a decrease of tumor weight in mice with triple negative breast cancer. However, the tumors were most visibly reduced when naked dendrimers were injected.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a nosiče léků $7 D004337
650    _2
$a molekulární struktura $7 D015394
650    12
$a ruthenium $x chemie $7 D012428
650    12
$a triple-negativní karcinom prsu $x farmakoterapie $7 D064726
650    _2
$a počítačová simulace $7 D003198
650    12
$a protinádorové látky $x chemie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a komplexní sloučeniny $x chemie $7 D056831
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
655    _2
$a časopisecké články $7 D016428
700    1_
$a Maly, Marek $u Department of Physics, Faculty of Science, J.E. Purkyně University in Ústí nad Labem, Pasteurova 15, 400 96 Ústí nad Labem, Czech Republic
700    1_
$a Wójkowska, Dagmara $u Department of Haemostatic Disorders, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka st. 6/8, 92-215 Lodz, Poland
700    1_
$a Karolczak, Kamil $u Department of Haemostatic Disorders, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka st. 6/8, 92-215 Lodz, Poland
700    1_
$a Skiba, Elżbieta $u Institute of General and Ecological Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924 Łódź, Poland
700    1_
$a Hołota, Marcin $u Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland
700    1_
$a Kubczak, Małgorzata $u Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland
700    1_
$a Ortega, Paula $u Universidad de Alcalá, Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain; Instituto de Investigación Sanitaria Ramón y Cajal, IRYCIS, Spain
700    1_
$a Watala, Cezary $u Department of Haemostatic Disorders, Faculty of Health Sciences, Medical University of Lodz, Mazowiecka st. 6/8, 92-215 Lodz, Poland
700    1_
$a Javier de la Mata, F $u Universidad de Alcalá, Department of Organic and Inorganic Chemistry, and Research Institute in Chemistry "Andrés M. del Río" (IQAR), Madrid, Spain; Instituto de Investigación Sanitaria Ramón y Cajal, IRYCIS, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
700    1_
$a Bryszewska, Maria $u Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland
700    1_
$a Ionov, Maksim $u Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Poland
773    0_
$w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 636, č. - (2023), s. 122784
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36858135 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132444 $b ABA008
999    __
$a ok $b bmc $g 1963112 $s 1196755
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 636 $c - $d 122784 $e 20230228 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
LZP    __
$a Pubmed-20230718
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace